IP Library Granted Patent US 12,226,374
Granted Patent B2
US 12,226,374 · App. 17/816,071 · Granted Feb 18, 2025

Compositions comprising quinone and/or quinol and methods of preparations and use thereof

Inventor: Barrie Tan (Hadley, MA)
Assignee: American River Nutrition, LLC
A61K31/12A61K9/0053A61K31/09
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,374
App. No.
17/816,071
Granted
Feb 18, 2025
Kind
B2
Abstract

The present embodiments are directed to compositions of quinones and/or quinols, such as, but not limited to, ubiquinone and/or ubiquinol, vitamin E quinone and/or vitamin E quinol, vitamin K quinone and/or vitamin K quinol, menaquinones and/or menaquinols, and pyrroloquinoline quinone and/or pyrroloquinoline quinol, and methods for preparations and use thereof. The present embodiments are also directed to compositions of reduced forms of curcuminoid and methods for preparations and use thereof.

Claims (64)

1. A composition comprising:

Compound A having the formula of

Compound B having the formula of

Compound C having the formula of

Compound D having the formula of

 and

optionally a non-toxic solvent with the proviso that the non-toxic solvent is not ethanol,

wherein:

R 5 is H, OH, NH 2 , NO 2 , R 6 —C(═O)—, optionally substituted carbocycle, optionally substituted aryl group, optionally substituted heteroaryl group, branched or unbranched alkyl alcohol, halo, branched or unbranched alkyl, branched or unbranched alkenyl, branched or unbranched alkenyl ester, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl, nitrite, or alkylsulfanyl; and

R 1 , R 2 , R 3 , R 4 , R 6 , and R 8 are each, independently, H, OH, NH 2 , NO 2 , optionally substituted carbocycle, optionally substituted aryl group, optionally substituted heteroaryl group, branched or unbranched alkyl alcohol, halo, branched or unbranched alkyl, branched or unbranched alkenyl, branched or unbranched carboxylic acid, branched or unbranched alkyl ester, branched or unbranched alkenyl ester, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl, nitrite, or alkylsulfanyl; or R 2 and R 3 are together optionally substituted cycloalkyl, optionally substituted cycloheteroalkyl, optionally substituted aryl, or optionally substituted heteroaryl; and

wherein the Compound A has the formula of

 wherein n, o, p, q, and r are each, independently, 1-20.

2. The composition of claim 1 , wherein Compound B has the formula of

3. The composition of claim 2 , wherein Compound B has the formula of

4. The composition of claim 1 , wherein the non-toxic solvent is a terpenoid having the formula of

and m is 0-10.

5. The composition of claim 4 , wherein the terpenoid has the formula of

6. The composition of claim 1 , wherein the non-toxic solvent is

7. The composition of claim 1 , wherein Compound A is

and o is 3.

8. The composition of claim 1 , wherein Compound A is

9. The composition of claim 1 , wherein the composition comprises:

Compound A having the formula of

Compound B having the formula of

Compound C having the formula of

 and

the solvent having the formula of

10. The composition of claim 9 , wherein the composition comprises:

Compound A having the formula of

Compound B having the formula of

Compound C having the formula of

 and

the solvent having the formula of

11. The composition of claim 1 , wherein the weight ratio of the total amount of Compound A and Compound C: Compound B is in a range of about 5:1 to about 1:5, about 3:1 to about 1:3, or about 2:1 to about 1:2.

12. The composition of claim 1 , wherein the weight ratio of Compound A: Compound C is in a range of about 99.9:0.1 to about 0.1:99.9, 40:60 to about 1:99, about 20:80 to about 1:99, about 15:85 to about 7:93, about 13:87 to about 7:93, about 13:87 to about 8:92, or about 13:87 to about 8:91.

13. The composition of claim 1 , the composition further comprises an antioxidant in an effective amount to reduce or prevent the oxidation of the compound for Formula III or Formula VI.

14. The composition of claim 13 , wherein the antioxidant is a-tocopherol, b-tocopherol, g-tocopherol, d-tocopherol, a-tocotrienol, b-tocotrienol, g-tocotrienol, d-tocotrienol, or glutathione, or a combination thereof.

15. The composition of claim 1 , wherein the composition further comprises vitamin B6.

16. The composition of claim 1 , wherein the composition is formulated in a form suitable for oral consumption or oral administration and the form is selected from the group consisting of a softgel, a capsule, 2-piece liquid-filled capsule, a bar, confectionary, chocolate, a powder, an oral suspension, a tablet, a pill, a hard-shell, a truffle, a ganache, a truffle ganache, a gum, and a chewable form.

17. A method, the method comprising:

mitigating or treating statin-induced CoQ10 diseases in a subject comprising administering to the subject the composition of claim 1 ;

improving cardiac functions, increasing energy, increasing bone mineralization, prevention of joint osteophyte growth, prevention and reversion of gall and kidney stones, reversal of arterial calcification, preventing statin-induced myopathy, preventing blood-thinning med-induced dementia, increasing myogenesis, preventing sarcopenia, preventing cancer-induced cachexia, increasing zest and thrive, preventing fibromyalgia, decreasing fatigue, preventing energy deficits, or improving general metabolic synthesis of proteins, CoQ10, or Vitamin K2 in a subject comprising administering to the subject the composition of claim 1 ;

increasing bioavailability and bioaccessibility of a second composition in a subject comprising administering to the subject the composition of claim 1 with the second composition;

increasing absorption into an endothelial or internal surface skin of a dermatological composition, comprising administering to a subject the composition of claim 1 with the dermatological composition;

improving mitochondrial function or increasing mitochondrial reproduction in a subject comprising administering to a subject the composition of claim 1 ;

improving neurological regeneration in a subject comprising administering to the subject the composition of claim 1 ; or

mitigating or treating nonalcoholic fatty liver in a subject comprising administering to a subject the composition of claim 1 ;

wherein the subject of any of the foregoing can optionally be a subject in need thereof.

18. The composition of claim 1 , wherein the composition comprises:

Compound A having the formula of

Compound B having the formula of

Compound C having the formula of

Compound D having the formula of

and

the solvent having the formula of

19. A method, the method comprising:

mitigating or treating statin-induced CoQ10 diseases in a subject comprising administering to the subject the composition of claim 18 ;

improving cardiac functions, increasing energy, increasing bone mineralization, prevention of joint osteophyte growth, prevention and reversion of gall and kidney stones, reversal of arterial calcification, preventing statin-induced myopathy, preventing blood-thinning med-induced dementia, increasing myogenesis, preventing sarcopenia, preventing cancer-induced cachexia, increasing zest and thrive, preventing fibromyalgia, decreasing fatigue, preventing energy deficits, or improving general metabolic synthesis of proteins, CoQ10, or Vitamin K2 in a subject comprising administering to the subject the composition of claim 18 ;

increasing bioavailability and bioaccessibility of a second composition in a subject comprising administering to the subject the composition of claim 18 with the second composition;

increasing absorption into an endothelial or internal surface skin of a dermatological composition, comprising administering to a subject the composition of claim 18 with the dermatological composition;

improving mitochondrial function or increasing mitochondrial reproduction in a subject comprising administering to a subject the composition of claim 18 ;

improving neurological regeneration in a subject comprising administering to the subject the composition of claim 18 ; or

mitigating or treating nonalcoholic fatty liver in a subject comprising administering to a subject the composition of claim 18 ;

wherein the subject of any of the foregoing can optionally be a subject in need thereof.

Assignments (3)
SECURITY INTEREST Recorded Oct 20, 2025
From: DESIGNS FOR HEALTH, INC.
To: TCW PT MANAGEMENT COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 072608/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2025
From: AMERICAN RIVER NUTRITION, LLC
To: DESIGNS FOR HEALTH, INC.
Reel/Frame 071596/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2022
From: TAN, BARRIE
To: AMERICAN RIVER NUTRITION, LLC
Reel/Frame 060671/0930 →
Continuity (3)
Division 16829868 · Mar 25, 2020
Provisional Application 62915649 · Oct 16, 2019
Related Publication 20220409553A1 · Dec 29, 2022
References Cited (105)
US 3863633A · Ryde et al. · 1975 [cited by applicant]
US 3867519A · Michaels · 1975 [cited by applicant]
US 3868445A · Ryde et al. · 1975 [cited by applicant]
US 3960150A · Hussain et al. · 1976 [cited by applicant]
US 3963025A · Whitaker et al. · 1976 [cited by applicant]
US 4186184A · Zaffaroni · 1980 [cited by applicant]
US 4303637A · Shell et al. · 1981 [cited by applicant]
US 5443505A · Wong et al. · 1995 [cited by applicant]
US 5869079A · Wong et al. · 1999 [cited by applicant]
US 6056971A · Goldman · 2000 [cited by applicant]
US 6184255B1 · Mae et al. · 2001 [cited by applicant]
US 6461842B1 · Matsuda et al. · 2002 [cited by applicant]
US 6623734B2 · Udell et al. · 2003 [cited by applicant]
US 6740338B1 · Chopra · 2004 [cited by applicant]
US 6762037B1 · Matsuda et al. · 2004 [cited by applicant]
US 6939897B2 · Fujii et al. · 2005 [cited by applicant]
US 7105709B2 · Ueda et al. · 2006 [cited by applicant]
US 7145044B2 · Ueda et al. · 2006 [cited by applicant]
US 7208639B2 · Ueda et al. · 2007 [cited by applicant]
US 7320883B2 · Matsuda et al. · 2008 [cited by applicant]
US 7358402B2 · Ueda et al. · 2008 [cited by applicant]
US 7364751B2 · Fujii et al. · 2008 [cited by applicant]
US 7402413B2 · Matsuda et al. · 2008 [cited by applicant]
US 7445793B2 · Niwa et al. · 2008 [cited by applicant]
US 7524993B2 · Ueda et al. · 2009 [cited by applicant]
US 7678404B2 · Shiraishi et al. · 2010 [cited by applicant]
US 7708990B2 · Fujii et al. · 2010 [cited by applicant]
US 7754205B2 · Fujii et al. · 2010 [cited by applicant]
US 7829080B2 · Ueda et al. · 2010 [cited by applicant]
US 7897169B2 · Ueda et al. · 2011 [cited by applicant]
US 7910340B2 · Yajima et al. · 2011 [cited by applicant]
US 7989006B2 · Tan · 2011 [cited by applicant]
US 8003828B2 · Ueda et al. · 2011 [cited by applicant]
US 8063254B2 · Ueda et al. · 2011 [cited by applicant]
US 8067217B2 · Ueda et al. · 2011 [cited by applicant]
US 8124072B2 · Fantuzzi · 2012 [cited by applicant]
US 8163525B2 · Matsuda et al. · 2012 [cited by applicant]
US 8168618B2 · Kawahara et al. · 2012 [cited by applicant]
US 8173711B2 · Saito et al. · 2012 [cited by applicant]
US 8293290B2 · Tan · 2012 [cited by applicant]
US 8506956B2 · Ueda et al. · 2013 [cited by applicant]
US 8568779B2 · Kanaya et al. · 2013 [cited by applicant]
US 8574568B2 · Ueda et al. · 2013 [cited by applicant]
US 8703155B2 · Ueda et al. · 2014 [cited by applicant]
US 8753675B1 · Chopra · 2014 [cited by applicant]
US 8853464B2 · Ueda et al. · 2014 [cited by applicant]
US 8946303B2 · Fujii et al. · 2015 [cited by applicant]
US 9006493B2 · Kanaya et al. · 2015 [cited by applicant]
US 9040747B2 · Jikihara et al. · 2015 [cited by applicant]
US 9295656B2 · Ueda et al. · 2016 [cited by applicant]
US 9315839B2 · Yajima et al. · 2016 [cited by applicant]
US 9345672B2 · Fantuzzi · 2016 [cited by applicant]
US 9388109B2 · Kawachi et al. · 2016 [cited by applicant]
US 9440901B2 · Kawachi et al. · 2016 [cited by applicant]
US 9518004B2 · Koga et al. · 2016 [cited by applicant]
US 9532957B2 · Ueda et al. · 2017 [cited by applicant]
US 9556098B2 · Kawachi et al. · 2017 [cited by applicant]
US 9919017B2 · Yamaguchi et al. · 2018 [cited by applicant]
US 9926580B2 · Yajima et al. · 2018 [cited by applicant]
US 9949938B2 · Tan · 2018 [cited by applicant]
US 9981899B2 · Ueda et al. · 2018 [cited by applicant]
US 10239811B2 · Kanaya et al. · 2019 [cited by applicant]
US 11471426B2 · Tan · 2022 [cited by examiner]
US 20040202740A1 · Tan · 2004 [cited by applicant]
US 20050069996A1 · Yajima et al. · 2005 [cited by applicant]
US 20060246565A1 · Ueda et al. · 2006 [cited by applicant]
US 20070208086A1 · Lipshutz · 2007 [cited by applicant]
US 20080139649A1 · Barrow et al. · 2008 [cited by applicant]
US 20080160077A1 · Borowy-Borowski · 2008 [cited by applicant]
US 20080200732A1 · Upare et al. · 2008 [cited by applicant]
US 20100168249A1 · Kitamura et al. · 2010 [cited by applicant]
US 20110123505A1 · Ueda et al. · 2011 [cited by applicant]
US 20120323009A1 · Ikemoto et al. · 2012 [cited by applicant]
US 20130142767A1 · Yamaguchi et al. · 2013 [cited by applicant]
US 20150010520A1 · Tan · 2015 [cited by applicant]
US 20220409553A1 · Tan · 2022 [cited by applicant]
CL 202200929 · 2022 [cited by applicant]
KR 20130010649A · 2013 [cited by applicant]
WO 2012021394A1 · 2012 [cited by applicant]
WO 2018160618A1 · 2018 [cited by applicant]
Al Rajabi A, Booth SL, Peterson JW, Choi SW, Suttie JW, Shea MK, et al. Deuterium-labeled phylloquinone has tissue-specific conversion to menaquinone-4 among Fischer 344 male rats. J Nutr. 2012;142(5):841-5. Epub Mar. 2… [cited by applicant]
Campia I, Lussiana C, Pescarmona G, Ghigo D, Bosia A, Riganti C. Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis. British j… [cited by applicant]
Crane FL, Hatefi Y, RL Lester and C Widmer (1957). Isolation of a quinone from beef heart mitochondria, BBA 25:220-221. [cited by applicant]
First Substantive Report for Chilean Patent Application No. 202200929 dated Mar. 8, 2023. [cited by applicant]
Grammel, H, and Ghosh R. “Redox-State Dynamics of Ubiquinone-10 Imply Cooperative Regulation of Photosynthetic Membrane Expression in Rhodospirillum Rubrum.” Journal of Bacteriology, American Society for Microbiology (A… [cited by applicant]
Harshman SG, Shea MK, Fu X, Grusak MA, Smith D, Lamon-Fava S, et al. Atorvastatin Decreases Renal Menaquinone-4 Formation in C57BL/6 Male Mice. J Nutr. 2019;5 149(3):416-21. Epub Feb. 13, 2019. [cited by applicant]
Hirota Y, Nakagawa K, Sawada N, Okuda N, Suhara Y, Uchino Y, et al. Functional characterization of the vitamin K2 biosynthetic enzyme UBIAD1. PloS one. 2015;10(4): e0125737. Epub Apr. 16, 2015. [cited by applicant]
Houston MC, Treatment of Hypertension with Nutrition and Nutraceutical Supplements, Alternative and Complementary Therapies, vol. 25, Feb. 2019; and references on CoQ10 therein. [cited by applicant]
International Search Report and Written Opinion issued in PCT/US20/55917 dated Feb. 9, 2021. [cited by applicant]
Jeon et al., CAS: 158: 215735, 2013. [cited by applicant]
Marcuzzi A, Piscianz E, Zweyer M, Bortul R, Loganes C, Girardelli M, et al. Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology. International journal of molecular sciences… [cited by applicant]
Mattila P. Lehtonen M, and Kumpulainen J, Comparison of In-Line Connected Diode Array and Electrochemical Detectors in the High-Performance Liquid Chromatographic Analysis of Coenzymes Q9 and Q10 in Food Materials, The … [cited by applicant]
Meganathan R., Kwon, O., “Biosynthesis of Menaguinone (Vitamin K2) and Ubiquinone (CoQ)”, ASMscience.org, Dec. 23, 2009. [cited by applicant]
Nakagawa K, Hirota Y, Sawada N, Yuge N, Watanabe M, Uchino Y, et al. Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature. 2010;468(7320):117-21. 25 Epub Oct. 19, 2010. [cited by applicant]
Nickerson ML, Bosley AD, Weiss JS, Kostiha BN, Hirota Y, Brandt W, et al. The UBIAD1 prenyltransferase links menaquinone-4 [corrected] synthesis to cholesterol metabolic enzymes. Human mutation. 2013;34(2):317-29. Epub … [cited by applicant]
Non-Final Office Action mailed on Feb. 11, 2017 in U.S. Appl. No. 15/237,617. [cited by applicant]
Notice of Allowance mailed on Apr. 19, 2022 in U.S. Appl. No. 16/829,868. [cited by applicant]
Roginsky VA, Mohr D, Stocker R, Reduction of ubiquinone-1 by ascorbic acid is a catalytic and reversible process controlled by the concentration of molecular oxygen, Redox Report (1996) 2(1): p. 55-62. [cited by applicant]
Semeco, Arlene (2017), Nine Benefit of Coenzyme Q10 (www.healthline.com), Oct. 12, 2017; and references in CoQ10 therein. [cited by applicant]
Tan B, Mueller AM. Tocotrienols in Cardiometabolic Diseases. In: Watson R, Preedy V, editors. Tocotrienols: Vitamin E beyond Tocopherol: AOCS/CRC Press; 2008. p. 257-73. [cited by applicant]
Thomas et al. “Dietary Cosupplementation With Vitamin E and Coenzyme Q10 Inhibits Atherosclerosis in Apolipoprotein E Gene Knockout Mice”. Arterioscler Thromnb Vasc Biol. Apr. 2001, Vo 21, pp. 585-593, Abstract; p. 586,… [cited by applicant]
WholeFoods Interview, Jun. 2007 with Frederick Crane by Richard Passwater. [cited by applicant]
WholeFoods, Apr. 2019: p. 42-50, The absorption of Ubiquinone and Ubiquinol forms of Coenzyme Q10. [cited by applicant]
WholeFoods, Mar. 2019: p. 64-68, The functions and absorption of the Ubiquinone and Ubiquinol. [cited by applicant]
www.noberlprize.org., Peter Mitchell Nobel Lecture, Dec. 8, 1978. [cited by applicant]